logo-loader
viewSummit Therapeutics PLC

Summit Therapeutics appoints controlling shareholder and chairman Bob Duggan as CEO

The biotech billionaire was appointed as the company's executive chairman back in February

Summit Therapeutics PLC - Summit Therapeutics appoints controlling shareholder and chairman Bob Duggan as CEO

Summit Therapeutics PLC (NASDAQ:SMMT) has appointed its executive chairman and controlling shareholder, biotech billionaire Bob Duggan, as its new chief executive.

Duggan will retain his position as chair of the biotech group, while he will replace outgoing CEO Glyn Edwards, who has resigned with immediate effect after eight years of service, although he will remain an elected board member.

READ: Summit Therapeutics appoints controlling shareholder, biotech billionaire Bob Duggan as its executive chairman

“To build a viable Summit Therapeutics company will require, amongst many other factors, bringing on additional seasoned executives as well as raising additional financial capital over time. The anti-infective disease medicinal drug business has plus points as well as challenges. Initial disease cures are plus points. Lack of sustained cures caused by disease recurrence and when combined with ever growing multi spectrum drug resistance, in my opinion, form the Achille’s heel of today’s FDA approved anti-infective drugs”, Duggan said.

“Summit Therapeutics is engaged in very significant work. Infectious disease patients are in need of durable cures. Caregivers are in search of and in need of durable cures. Payers are in need of cost-effective medicinal drugs that substantially reduce the heavy financial burden of early disease recurrence post anti-infective drug treatment”, he added.

Duggan also said the company “has the potential and intends to play a meaningful role in [a] needed and wanted new era of increasingly patient friendly anti-infective drug therapy”.

Shares in Summit were 0.6% higher at US$3.30 in early trading in New York on Tuesday.

Quick facts: Summit Therapeutics PLC

Price: - -

AIM:SUMM
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics pleased with new BARDA partnership investment

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) Investor Relations Senior Director Michelle Avery sat down with Proactive's Christine Corrado at BIO CEO in New York. The company recently announced The Biomedical Advanced Research and Development Authority (BARDA) is investing a further $8.8mln...

on 02/10/2020

2 min read